Fifth Annual
TARGETING OCULAR DISORDERS
The Latest Targets, Pathways and Drug Delivery Methods

Speaker Highlights Include:

• Sparks Therapeutics, GenSight Biologics, Editas and several others discuss the latest gene therapy and gene editing breakthroughs for ocular disorders

• Leaders in ocular drug delivery provide their insights on key considerations when determining the right ocular drug delivery method for their products and challenges that they faced

• Experts from Verseon and KalVista Pharmaceuticals present VEGF independent treatments for DME

Healthtech.com/Targeting-Ocular-Disorders
With its complex structure and the breadth of ocular disorders, the eye presents unique challenges to drug discovery. Cambridge Healthtech Institute's Fifth Annual Targeting Ocular Disorders conference provides a platform to discuss novel targets and disease pathways, the latest drug delivery methods, and the most promising emerging therapies for both front and back of eye disorders. A special focus will be on gene therapy, stem cell therapies, and treatments outside of the well-established anti-VEGF monotherapies. The event will cover a broad range of diseases including but not limited to glaucoma, wet and dry age-related and diabetic macular degeneration, retinopathy and retinitis pigmentosa.
WEDNESDAY, SEPTEMBER 27

11:50 am Conference Registration Open

12:20 pm Plenary Keynote Program
(Click here for complete details)

2:00 Refreshment Break in the Exhibit Hall with Poster Viewing

GENE EDITING & GENE THERAPY BREAKTHROUGHS FOR OCULAR DISORDERS

2:45 Welcome Remarks
Lee Yuan, Conference Director, Cambridge Healthtech Institute

2:50 Chairperson's Opening Remarks
Bo Liang, Ph.D., President, R&D, IVIEW Therapeutics, Inc.

2:55 Lentiviral Gene Therapy for Ocular Disease
Scott Ellis, Ph.D., Head, Early Development, Oxford BioMedica
Oxford BioMedica's gene therapy for Parkinson's disease (ProSavin®) was the first ever lentiviral gene therapy directly administered in man, and its shared LentiVector® gene therapy platform is the basis of three ocular gene therapies currently under clinical evaluation as well as several earlier-stage programs in development. This talk will review our previous experience and current plans using the LentiVector® platform in the development of gene therapies for chronic ocular diseases.

3:25 Intravitreal Gene Therapy for Dry AMD
Jay S. Duker, M.D., Director, New England Eye Center; Professor and Chairman, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine; Founder, Hemera Biosciences
Dry age related macular degeneration (AMD) represents a significant cause of visual loss in the elderly but lacks an approved therapy. Inhibiting the complement system locally within the eye shows promise as a therapeutic intervention. Hemera Biosciences’ lead product, HMR59, is an AAV2 based gene therapy delivered intravitreally that blocks membrane attack complex (MAC) through the local production of soluble CD59. HMR59 is currently being tested in a Phase I clinical trial in eyes with severe dry AMD and geographic atrophy (GA).

3:55 Development of Sustain Release Povidone Iodine Ophthalmic Drop through Novel in situ Gel Formulation
Bo Liang, Ph.D., President, R&D, IVIEW Therapeutics, Inc.
IVIEW developed a long-acting povidone iodine (PVP-I) ophthalmic drop (IVIEW-1201) for the treatment of active infections of the conjunctiva and cornea by bacteria, mycobacteria, virus, fungus, or amoebic causes. There is currently no broadly effective therapy that treats all causes of infection and nothing is approved for the treatment of viral conjunctivitis. This represents a massive unmet need in ophthalmology. The novel in-situ gel formulation IVIEW-1201 where the effective concentration of PVP-I is maintained by the equilibrium between solution PVP-I and the gel bound components results in a long lasting, less toxic pharmacological effect.

4:25 Refreshment Break in the Exhibit Hall with Poster Viewing

5:00 Development of an Intravitreal AAV-Based Treatment for Wet Age-Related Macular Degeneration
Mehdi Gasmi, Ph.D., CTO & CSO, Adverum Biotechnologies

5:30 Optogenetic Therapy for Retinal Dystrophies
Anne Douar, Ph.D., Project Director, GenSight Biologics
Optogenetics aims at transferring a gene encoding for a light-sensitive molecule to restore photosensitivity in retinal cells that are still wired into the inner retina layers. The GS030 treatment combines such gene therapy based approach in combination with a photo-stimulating device to potentiate the biologics’ activity. Translational research has allowed to demonstrate the proof of concept in rodent and non-human primate models and to establish the safety profile of the product, paving the way to the first in human clinical trial currently in preparation.

6:00 A CRISPR Medicine Approach for Treating Leber Congenital Amaurosis Type 10
Gerald F. Cox, M.D., Ph.D., CMO, Editas Medicine
Leber congenital amaurosis type 10 (LCA10) is a rare infantile-onset retinal dystrophy caused by autosomal recessive mutations in the CEP290 gene. The most common LCA10 mutation, c.2991+1655A>G, creates a cryptic splice acceptor site in intron 26 that causes missplicing and leads to a non-functional protein. CRISPR/Cas9 is being applied to correct the underlying common genetic defect in LCA10, with the goal of providing a durable treatment that restores vision to patients.

6:30 Close of Day
THURSDAY, SEPTEMBER 28

7:30 am Registration Open

8:00 Interactive Breakout Discussion Groups with Continental Breakfast
Grab a cup of coffee and join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are available on the conference website.

GENE EDITING & GENE THERAPY BREAKTHROUGHS FOR OCULAR DISORDERS

9:00 Chairperson's Remarks
Naj Sharif, Ph.D., FARVO, FBPhS, Executive Director; Head, Global Alliances & External Research, Santen, Inc.

9:05 Investigational Gene Therapy for Inherited Retinal Dystrophies Due to Biallelic Mutations in RPE65
Daniel Chung, D.O., Clinical Ophthalmic Lead, Sparks Therapeutics
This presentation is a review of the latest results from a Phase III, open-label, randomized, controlled trial evaluating the safety and efficacy of AAV2-hRPE65v2 (SPK-RPE65) to treat inherited retinal dystrophies caused by biallelic mutations in the RPE65 gene, following adeno-associated virus mediated gene transfer to the retina.

NOVEL TARGETS & DISEASE PATHWAYS

9:35 Novel Glaucoma Drugs and Devices: Paving Paths towards Retinoprotection
Naj Sharif, Ph.D., FARVO, FBPhS, Executive Director; Head, Global Alliances & External Research, Santen, Inc.

Students may also benefit from presenting a poster. Here are some tips and benefits:

1. Showcase Your Research to 1,200+ Attendees: Within the expansive Exhibit Hall, stand by your poster and network with attendees. Distribute copies of journal articles or papers you have authored or contributed to.

2. Start a Future Collaboration and Meet a Potential Employer: Collect business cards and meet prospective collaborators who may be actively pursuing work in your field. Put together a short outline of the field(s) in which you seek collaborators or new professional challenges, and distribute those to the people you meet.

3. Expand Your Network: When you return to school/lab, add each person you meet to your LinkedIn connections. Keep in touch to share new ideas that may advance your own research or stature in the scientific community.
DRUG DELIVERY METHODS FOR OCULAR DISORDERS

11:50 The Potential for Treatments for Posterior Segment Eye Diseases Using a Suprachoroidal Injection Approach
Glenn Noronha, Ph.D., CSO, Clearside Biomedical, Inc.

We will outline the progression of the development of suprachoroidal administration of drug candidates with potential for the treatment of posterior segment eye diseases. Clearside has ongoing Phase III studies in noninfectious uveitis and in retinal vein occlusion, and a Phase I/II trial in diabetic macular edema as part of continued development. We will trace the progression from bench to animals through to clinical efforts, to make the case for this approach for the treatment of eye diseases.

12:20 pm Sponsored Presentation (Opportunity Available)

12:50 Session Break

1:00 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:50 Refreshment Break in the Exhibit Hall with Poster Viewing

2:35 Chairperson's Remarks
Sharon Klier, Vice President, Ophthalmology, Medical, Quark Pharmaceuticals

2:40 Novel Injectable Products for Treatment of Ocular Diseases
Ming Yang, Ph.D., Director, Research, Graybug Vision

Graybug Vision's lead product, GB-102, consists of an approved receptor tyrosine kinase inhibitor, sunitinib malate, that inhibits multiple pathogenic angiogenesis pathways known to be involved in choroidal neovascularization, the cause of neovascular AMD. Graybug Vision has incorporated sunitinib in its novel delivery system to allow a potential twice per year injection. Graybug Vision has also developed a library of compounds to treat glaucoma by lowering intraocular pressure alone or in combination with neuroprotection when injected twice per year into the subconjunctiva.

3:10 Sustained Micro-Dose Drug Delivery with Injectable Inserts: Current Status and Emerging Applications
Dario A. Paggiarino, M.D., Vice President, CMO, pSivida

Sustained linear-release, micro-dose delivery of antiviral and anti-inflammatory agents has evolved over the years from surgically implanted to injectable miniaturized inserts. The same technology showing long-term clinical benefit in past approved products is now being developed in the delivery of new agents and ocular conditions for which micro-dosing would be key in providing extended control of disease pathophysiology.

3:40 Session Break

3:55 Intracanalicular Inserts for Drug Delivery – Dextenza and Its Applications in Managing Ophthalmic Diseases
Amar Sawhney, Ph.D., Executive Chairman, Ocular Therapeutix

Dextenza promises to be the world's first single dose drug therapy to deliver the entire course of medication with a single placement. It is being developed for pain and inflammation following ocular surgery, allergic conjunctivitis, and other inflammatory conditions. Additionally, Ocular Therapeutix is investigating drugs for the treatment of ocular hypertension and glaucoma with a single placement that could provide therapy for up to 3 months. This talk will explore the design, development, and clinical data surrounding these drug products.

4:25 PANEL DISCUSSION: Pros and Cons of Ocular Drug Delivery Methods
Moderator: Elias Reichel, M.D., Professor and Vice Chair, Tufts University School of Medicine; Director, Vitreoretinal Diseases and Surgery Service, New England Eye Center; Founder, Hemera Biosciences
Panelists: Glenn Noronha, Ph.D., CSO, Clearside Biomedical, Inc.
Ming Yang, Ph.D., Director, Research, Graybug Vision
Amar Sawhney, Ph.D., Executive Chairman, Ocular Therapeutix
Dario A. Paggiarino, M.D., Vice President, CMO, pSivida

The panelists will discuss key considerations when determining the right ocular drug delivery method for their products and challenges that they faced. There will also be general discussion about the pros and cons of different delivery methods for the eye.

4:55 Close of Conference
Sponsorship, Exhibit, and Lead Generation Opportunities

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space, branding and networking with specific prospects. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company’s needs and budget. Signing on early will allow you to maximize exposure to qualified decision-makers.

Podium Presentations — Available within Main Agenda!
Showcase your solutions to a guaranteed, targeted audience through a 15- or 30-minute presentation during a specific conference program, breakfast, lunch, or separate from the main agenda within a pre-conference workshop. Package includes exhibit space, on-site branding, and access to cooperative marketing efforts by CHI. For the luncheon option, lunches are delivered to attendees who are already seated in the main session room. Presentations will sell out quickly, so sign on early to secure your talk!

One-on-One Meetings
Select your top prospects from the pre-conference registration list. CHI will reach out to your prospects and arrange the meeting for you. A minimum number of meetings will be guaranteed, depending on your marketing objectives and needs. A very limited number of these packages will be sold.

Reception / VIP Dinner / Hospitality Suite
Sponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects, helping you to make the most out of this invaluable opportunity. Evening will be customized according to sponsor’s objectives. (i.e. Purely social, Focus group, Reception style, plated dinner with specific conversation focus).

Exhibit
Exhibitors will enjoy facilitated networking opportunities with qualified delegates. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

Branding & Promotional Opportunities Include:
- Floor Standing Meter Boards
- Badge Lanyards
- Exhibit Hall Reception
- Conference Tote Bags
- Hotel Room Keys
- Program Guide Advertisement

Looking for additional ways to drive leads to your sales team?
CHI’s Lead Generation Programs will help you to obtain more targeted, quality leads throughout the year. We will mine our database of over 1,000,000 life science professionals to meet your specific needs. We guarantee a minimum of 100 leads per program! Opportunities include:
- White Papers
- Webinar
- Custom Market Research Survey
- Podcasts

For additional sponsorship & exhibit information, please contact:
Rod Eymael
Manager, Business Development
T: (+1) 781-247-6286
E: reymael@healthtech.com
The Westin Copley Place  
10 Huntington Ave.  
Boston, MA 02116  
T: 617-262-9600

Discounted Room Rate: $305  
Res Cutoff: August 28, 2017

RESERVATIONS AND ADDITIONAL TRAVEL INFORMATION:

Go to the travel page of  
Healthtech.com/Targeting-Ocular-Disorders
How to Register: Healthtech.com/Targeting-Ocular-Disorders
reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288
Please use keycode EYE F when registering

Fifth Annual
TARGETING
OCULAR DISORDERS

The Latest Targets, Pathways and Drug Delivery Methods
September 27-28, 2017
The Westin Copley Place | Boston, MA

Pricing and Registration Information

CONFERENCE PRICING

Targeting Ocular Disorders conference pricing:
Includes access to (1) conference, (excludes short courses and/or Symposium)

<table>
<thead>
<tr>
<th>Academic, Government, Commercial</th>
<th>Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration after August 18, 2017</td>
<td>$1,979</td>
</tr>
</tbody>
</table>

CONFERENCE DISCOUNTS

Poster Submission - Discount ($50 Off): Poster abstracts are due by August 4, 2017. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com. *CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

REGISTER 3 - 4th IS FREE: Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.

Alumni Discount: Cambridge Healthtech Institute (CHI) appreciates your past participation at Targeting Ocular Disorders. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate.

Group Discounts: Discounts are available for multiple attendees from the same organization. For more information on group rates contact Jeff Knight, jknight@healthtech.com at +1-781-247-6264.

If you are unable to attend but would like to purchase the Targeting Ocular Disorders CD for $750 (plus shipping), please visit Healthtech.com/Targeting-Ocular-Disorders. Massachusetts delivery will include sales tax.